Late-stage opportunity Leverage 4DMT's Phase 3 4D-150 program for wet age-related macular degeneration to position partnerships or licensing deals that accelerate access to multi-year anti-VEGF delivery with reduced treatment burdens for ophthalmology networks.

CFTR gene therapy Target large cystic fibrosis care centers and payer collaborations to explore aerosol-delivered CFTR transgene therapies via 4D-710, highlighting potential for improved patient compliance and broader market adoption in respiratory genetics.

Strategic financing Assess co-development or milestone-based funding agreements given the company’s existing sizable financing and credit facilities, offering financial structures that de-risk expansion into new indications and geographies.

Clinical data momentum Capitalize on two-year PRISM Phase IIb updates and upcoming ASRS presentations to create sales narratives for ophthalmology practices, payers, and biopharma partners around durable treatment paradigms and reduced administration frequency.

Operational readiness Engage with 4DMT’s corporate team to align on joint development plans, manufacturing scalability, and market access strategies leveraging their tech stack and global partner ecosystem for efficient clinical-to-commercial transitions.